Evaluation of the automated LIAISON® SARS-CoV-2 TrimericS IgG assay for the detection of circulating antibodies
- PMID: 33711225
- DOI: 10.1515/cclm-2021-0023
Evaluation of the automated LIAISON® SARS-CoV-2 TrimericS IgG assay for the detection of circulating antibodies
Abstract
Objectives: COVID-19 has brought about tests from many manufacturers. While molecular and rapid antigen tests are targeted for early diagnosis, immunoassays have a larger role in epidemiological studies, understanding longitudinal immunity, and in vaccine development and response.
Methods: The performance of the LIAISON® SARS-CoV-2 TrimericS IgG assay was evaluated against the Beckman ACCESS SARS-CoV-2 IgG assay in New Mexico, and against the Siemens ADVIA Centaur COV2G assay in New York. Discordant samples were parsed using a microneutralization assay.
Results: A SARS-CoV-2 antibody positivity rate of 23.8% was observed in the samples tested in New York (September 2020), while in the same month the positivity rate was 1.5% in New Mexico. Positive and negative agreement were 67.6% (95% CI 49.5-82.6%) and 99.8% (95% CI 99.5-99.9%), respectively, with the Beckman test, and 98.0% (95% CI 95.7-99.3%) and 94.8% (95% CI 93.4-96.0%), respectively, with the Siemens test. Receiver operating characteristic analysis for the detection of SARS-CoV-2 antibodies discloses an AUC, area under the curve, of 0.996 (95% CI 0.992-0.999) for the LIAISON® SARS-CoV-2 TrimericS IgG assay. The criterion associated to the Youden Index was determined to be >12.9 kAU/L with a sensitivity of 99.44% and a specificity of 99.82%.
Conclusions: The LIAISON® SARS-CoV-2 TrimericS IgG assay is highly sensitive and specific. The balance of these parameters, without emphasis on high specificity alone, is particularly important when applied to high prevalence populations, where a highly sensitive assay will result in reporting a lower number of false negative subjects.
Keywords: COVID-19; RBD; SARS-CoV-2; immunoassays; neutralization; serological; spike; trimeric; vaccine.
© 2021 Fabrizio Bonelli et al., published by De Gruyter, Berlin/Boston.
References
-
- Dhama, K, Sharun, K, Tiwari, R, Sircar, S, Bhat, S, Malik, YS, et al.. Coronavirus disease 2019–COVID-19. Clin Microbiol Rev 2020;33e:00028. https://doi.org/10.1128/CMR.00028-20.
-
- COVID-19 dashboard by the Center for Systems Science and Engineering (CSSE). Available from: https://coronavirus.jhu.edu.
-
- Machhi, J, Herskovitz, J, Senan, AM, Dutta, D, Nath, B, Oleynikov, MD, et al.. The natural history, pathobiology, and clinical manifestations of SARS-CoV-2 infections. J Neuroimmune Pharmacol 2020;15:359–86.
-
- Jeyanathan, M, Afkhami, S, Smaill, F, Miller, MS, Lichty, BD, Xing, Z. Immunological considerations for COVID-19 vaccine strategies. Nat Rev Immunol 2020;20:615–32. https://doi.org/10.1038/s41577-020-00434-6.
-
- Black, S, Bloom, DE, Kaslow, DC, Pecetta, S, Rappuoli, R. Transforming vaccine development. Semin Immunol 2020;50:101413. https://doi.org/10.1016/j.smim.2020.101413.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous